Fertinex is a drug owned by Serono Laboratories Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 16, 2015. Details of Fertinex's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5767067 | Follicle stimulating hormone and pharmaceutical compositions containing same |
Jun, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Fertinex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fertinex's family patents as well as insights into ongoing legal events on those patents.
Fertinex's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Fertinex's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 16, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Fertinex Generics:
There are no approved generic versions for Fertinex as of now.
About Fertinex
Fertinex is a drug owned by Serono Laboratories Inc. Fertinex uses Urofollitropin as an active ingredient. Fertinex was launched by Serono in 1986.
Approval Date:
Fertinex was approved by FDA for market use on 18 September, 1986.
Active Ingredient:
Fertinex uses Urofollitropin as the active ingredient. Check out other Drugs and Companies using Urofollitropin ingredient
Dosage:
Fertinex is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 150 IU/AMP | INJECTABLE | Discontinued | SUBCUTANEOUS |
| 75 IU/AMP | INJECTABLE | Discontinued | SUBCUTANEOUS |